Press releases

December 27, 2019
Regulatory

New major order from China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the fourth quarter of approximately SEK 16.5 million.

November 07, 2019
Regulatory

Interim report for Q3 2019

The new license agreement with Zimmer Biomet contributed to that we delivered the strongest quarter to date for Bactiguard as a listed company. The partnership with one of the three largest orthopedic companies in the world confirms the strength of Bactiguard's technology in a global perspective and a new medical application for long-term use. The financial impact of the agreement also shows that our growth strategy works.

November 04, 2019

Invitation to presentation of Bactiguard’s interim report on November 7, 2019

Bactiguard Holding AB (publ) publishes the interim report for the third quarter on Thursday November 7, 2019 at 7:30 CET.

October 23, 2019
Regulatory

Nomination Committee appointed for the Annual General Meeting 2020

The members of the Nomination Committee for the Annual General Meeting of Bactiguard Holding AB (publ), to be held on Tuesday 28 April 2020 at the company’s headoffice in Botkyrka, have now been appoined.

September 29, 2019
Regulatory

New major order from China

Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.

September 27, 2019
Regulatory

Bactiguard signs global license agreement with Zimmer Biomet

Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.

September 25, 2019

Bactiguard’s central venous catheters approved in Mexico

The product approval for Bactiguard's central venous catheters has been announced by the Mexican Ministry of Health. This provides new opportunities for Bactiguard in providing effective infection prevention for the most vulnerable patients in the second biggest market in Latin America.

September 10, 2019

Bactiguard’s urinary catheters approved for reimbursement in the Dutch market

Bactiguard’s indwelling urinary catheters (Foleys) are now approved for reimbursement in the Netherlands, which means that healthcare providers in the home care market can provide patients with Bactiguard's products for infection prevention and improve their quality of life.

September 05, 2019

Bactiguard recruits experienced Chief Medical and Technology Officer

Stefan Grass with extensive clinical experience as a physician and researcher, combined with senior positions in the pharmaceutical industry, has been recruited to a newly established, global role as Chief Medical and Technology Officer. He will assume his position in October 2019 and report to the CEO.

August 08, 2019
Regulatory

Interim report for Q2 2019

The second quarter of 2019 was eventful. We increased our market coverage, secured funding for a very interesting research and development project, broadened the clinical evidence and strengthened executive management. Revenues and earnings were weaker than last year, but one must bear in mind that the second quarter 2018 was very strong.

Pages